Condition
Arthropathy, Neurogenic
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02386579CompletedPrimary
Characterization of Local and Systemic Bone Markers in Diabetes Patients With Charcot Osteoarthropathy
NCT00069329Phase 1Terminated
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
NCT01370837Not ApplicableCompleted
Neurogenic Inflammation in Diabetes
Showing all 3 trials